TKPYY.PK: Takeda Pharma Market Currents - On the Move

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Monday, January 7, 12:12 PM Affymax (AFFY +5.4%) and Japanese drug maker Takeda Pharmaceuticals (TKPYY.PK) have entered into a supply agreement for sourcing and supply of Omontys Injection with DSI Renal. Financial terms weren't disclosed, but the agreement allows DSI Renal to purchase the drug for use within its organization, provide discounts and rebates on the product in its selected centers, and then, based on ongoing evaluation, potentially expand to additional facilities. Comment! [Healthcare, On the Move]
Tuesday, September 25, 2012, 4:42 PM Sucampo Pharmaceuticals (SCMP) and Takeda Pharmaceuticals (TKPYY.PK) say the FDA,has granted priority review of their supplemental new drug application for an additional indication for Amitiza, a treatment for opioid-induced constipation in patients with chronic, non-cancer pain. A decision is expected by late January 2013. Shares +7% AH. Comment! [Healthcare, On the Move]
Thursday, September 13, 2012, 9:22 AM Apricus Biosciences (APRI) +12.5% premarket after announcing it has licensed Takeda Pharmaceuticals (TKPHF.PK, TKPYY.PK) to market Vitaros, its erectile dysfunction drug, in the U.K. Takeda will pay APRI an undisclosed upfront payment and milestone payments of up to 35M euros. 1 Comment [Healthcare, On the Move]
Friday, July 27, 2012, 4:18 PM Furiex Pharmaceuticals (FURX +5.5%) ramped higher into the close after confirming that Takeda Pharmaceutical (TKPYY.PK) has resubmitted New Drug Applications to the FDA for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone for treating adult type 2 diabetes. Under it's agreement with Takeda, FURX is eligible to receive a $25M milestone payment for the approval of the first of these two NDAs, as well as additonal royalties and sales-based milestones. Comment! [Healthcare, Global & FX, On the Move]
Monday, July 2, 2012, 2:38 PM Piper Jaffray looks at other potential takeout candidates in the biotech space post-Amylin, highlighting BioMarin (BMRN +3.8%), Affymax (AFFY +1%), Theravance (THRX +8.3%), and Rigel Pharmaceuticals (RIGL +2.3%) all as potential candidates. Piper notes that BioMarin could fetch as much as $79 per share, and notes that Japanese drug heavyweight Takeda Pharmaceuticals (TKPYY.PK) could be the most likely suitor for Affymax. Comment! [Healthcare, On the Move, M&A]
Thursday, April 26, 2012, 8:36 AM Furiex Pharmaceuticals (FURX) -27% premarket after the company says the FDA requested further data from partner Takeda Pharmaceutical (TKPYY.PK) regarding the new drug applications for alogliptin and the fixed-dose combination therapy alogliptin and pioglitazone. Comment! [Healthcare, On the Move]
Tuesday, April 10, 2012, 10:39 AM Affymax (AFFY +2.4%) says it received a $50M development-milestone payment from Takeda Pharmaceutical (TKPYY.PK), triggered by the FDA's approval of its Omontys anemia drug late last month. Comment! [On the Move]
Wednesday, March 28, 2012, 3:09 PM Amylin (AMLN +48.6%) investors cheer the rumor it rejected a $3.5B offer from Bristol-Myers Squibb, and analysts expect higher bids. Deutsche Bank says AMLN could be worth up to $31/share given an "acquirer with diabetes sales force can cut SG&A by 80% and R&D by 40%." Piper Jaffray names BMY, MRK and TKPYY.PK as potential sutiors; Leerink Swann suggests AZN. Comment! [Healthcare, M&A, On the Move]
Friday, January 13, 2012, 2:36 PM Seattle Genetics (SGEN -4.8%) and Takeda Pharmaceutical (TKPYY.PK -1.00%) dip after the FDA says it's seen three cases of serious brain infection among patients being treated with their jointly-produced lymphoma drug Adcetris, and strengthened the drug's warning label. Comment! [Healthcare, On the Move]

TKPYY.PK Takeda Pharma

TKPYY.PK

Takeda Pharma